You are in: eMedicine Specialties > Physical Medicine and Rehabilitation > LUMBAR SPINE DISORDERS Lumbar Compression FractureArticle Last Updated: Feb 10, 2007AUTHOR AND EDITOR INFORMATIONAuthor: Andrew L Sherman, MD, Assistant Professor, Departments of Neurological Surgery, Orthopedics, and Rehabilitation, University of Miami Andrew L Sherman is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, American Association of Neuromuscular and Electrodiagnostic Medicine, American College of Sports Medicine, and American Medical Association Coauthor(s): Nizam Razack, MD, Assistant Professor, Department of Neurological Surgery, Miami Spine Institute, University of Miami Editors: Curtis W Slipman, MD, Director, University of Pennsylvania Spine Center, Associate Professor, Department of Physical Medicine and Rehabilitation, University of Pennsylvania Medical Center; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Patrick M Foye, MD, FAAPMR, FAAEM, Associate Professor of Physical Medicine and Rehabilitation, Co-Director of Musculoskeletal Fellowship, Co-Director of Back Pain Clinic, Director of Coccyx Pain (Tailbone Pain, Coccydynia) Service, University of Medicine and Dentistry of New Jersey, New Jersey Medical School; Kelly L Allen, MD, Consulting Staff, Department of Physical Medicine and Rehabilitation, Lourdes Regional Rehabilitation Center, Our Lady of Lourdes Medical Center; Rene Cailliet, MD, Professor-Chairman Emeritus, Department of Rehabilitation Medicine, University of Southern California School of Medicine; Former Director, Department of Rehabilitation Medicine, Santa Monica Hospital Medical Center Author and Editor Disclosure Synonyms and related keywords: lumbar crush fracture, osteoporotic fracture, collapse fracture, osteoporosis, vertebra fracture, vertebral fracture, burst fracture, wedge fracture, spinal wedge fracture, vertebroplasty, kyphoplasty INTRODUCTIONBackgroundThe lumbar vertebrae are the 5 largest and strongest of all vertebrae in the spine. These vertebrae compose the lower back. They begin at the start of the lumbar curve (ie, the thoracolumbar junction) and extend to the sacrum. The strongest stabilizing muscles of the spine attach to the lumbar vertebrae. End-stage osteoporosis often culminates with bony fractures. Fractures occur most commonly in the hips, wrists, arms, and spine. Osteoporotic spine fractures are unique because they may occur without apparent trauma. A thorough diagnostic workup is always required to rule out malignancy. In the past, treatment options were quite limited, with bracing and rest prescribed most often. While many patients improved with this regimen, some did not and were left with chronic, disabling pain. Suh and Lyles found that vertebral compression fractures were associated with significant performance impairments in physical, functional, and psychosocial domains in older women. However, this population now has new medical and surgical options that can relieve the severe pain and disability from a compression fracture. PathophysiologyThe lumbar spine provides for both stability and support when humans ambulate. The posture of the spine (ie, a proper lumbar curve) allows humans to stay balanced in an upright position and is based on the proper rectangular shape of the spine and the elastic disks in between. Therefore, any injury that changes the shape of the lumbar spine invariably changes the posture of the spine and increases or decreases the lumbar curve. Consequently, this affects the other curves of the thoracic and cervical spine in a negative manner as the body attempts to maintain an upright posture. Lumbar compression fractures, therefore, can be a devastating injury for 2 reasons. First, fractures can cause direct bony pain from the fracture itself, and this pain sometimes does not resolve. Second, the fracture can alter the mechanics of the posture. Most often, the result is an increase in thoracic kyphosis, sometimes to the point that the patient cannot stand upright. In trying to maintain their ability to walk, patients who are kyphotic report secondary pain in their hips, sacroiliac joints, and spinal joints. Patients with kyphotic posture are also at risk of falls and accidents, increasing the risk of secondary fractures in the spine and elsewhere. Fractures in the lumbar spine occur for a number of reasons. In younger patients, fractures are usually due to violent trauma. Car accidents frequently cause flexion and flexion distraction injuries. Patients who jump or fall from high distances experience burst fractures. These fractures can also result in serious neurological injury. In older patients, the cause is usually nontraumatic or from a nonexternal trauma such as a fall. The most common reason these fractures occur in geriatric patients is underlying osteoporosis. Finally, other factors that can contribute to the occurrence of compression fractures include pathologic factors, including malignancy and infections. Traumatic fractures A few different types of fractures can occur in the lumbar (or thoracic) spine. Classification of these fractures is based on the 3-column anatomic theories of Denis. The Denis system, however, was created to classify traumatic fractures. A similar classification system does not exist for compression fractures. The main reason to use such a classification is to help determine if the fracture is stable. Instability in the Denis system implies that damage has occurred to at least 2 of the anterior, middle, or posterior columns of the lumbar spine.
When any of the above injuries occurs with a severe rotational force, the degree of injury and amount of instability increases. Nontraumatic fractures In osteoporosis, osteoclastic activity exceeds osteoblastic activity, resulting in a generalized decrease in bone density. The osteoporosis softens the bone to the point even a minor fall on the tailbone, causing an axial load or flexion moment, results in one or more compression fractures (see Image 1). The fracture is usually wedge shaped. Without correction, a wedge fracture invariably increases the patient's degree of kyphosis. The most common malignancy-related factor in the spine that can cause a fracture is metastasis. Primary cancers that spread through hematologic dissemination are the most common to metastasize to the spine. These include cancers of the prostate, kidneys, breasts, and lungs. Melanoma is less common but more aggressive. The most common primary cancer of the spine is multiple myeloma, but others (eg, osteosarcoma, aneurysmal bone cyst, hemangioma) can also manifest as a spine fracture. Spinal infections usually start in the lumbar disk. From the disk, the infection spreads to bone, resulting in osteomyelitis. Severe pain is the hallmark sign. The exception is spinal tuberculosis or Pott disease. In this case, the disk spaces are typically spared and a compression fracture may be the initial manifestation that leads to its discovery. FrequencyUnited StatesMost fractures of the lumbar spine that require operative treatment occur at the thoracolumbar junction. These injuries are primarily traumatic in origin. Most nontraumatic lumbar fractures are osteoporotic in origin. These are almost invariably wedge-type compression fractures. Osteoporosis affects 30 million people in the United States. In 1992, at least 1.2 million fractures occurred due to osteoporosis, and the number surely has increased since then. Approximately 50% of all osteoporotic fractures are vertebral. Approximately one third of those injuries are lumbar, one third are thoracolumbar, and one third are thoracic in origin. Additionally, 75% of women older than 65 years who have scoliosis have at least 1 osteoporotic wedge fracture. Mortality/Morbidity
SexOsteoporosis occurs primarily in postmenopausal women. Type 1 osteoporosis occurs in women aged 51-65 years and is associated with wrist and vertebral fractures. Estrogen deficiency is the main pathogenic factor. Type 2 osteoporosis (senile type) is observed in women and men older than 75 years, in a 2:1 ratio of women to men. AgeIn young and middle-aged adults, the most common form of lumbar fracture is traumatic in origin. High-velocity falls can cause burst fractures, and seat-belt injuries can cause wedge fractures. As stated above, women aged 51-65 years develop type 1 osteoporosis. After age 75 years, men also begin to develop type 2 osteoporosis. CLINICALHistoryMidline back pain is the hallmark symptom of lumbar compression fractures. The pain is axial, nonradiating, aching, or stabbing in quality and may be severe and disabling. The patient should report back pain at the level where the fracture is seen on radiographs. Young adults may present with severe back pain after a trauma such as a fall or motor vehicle accident. Reports lower extremity weakness or numbness are important signs of neurologic injury from the fracture. Recently, Gibson et al presented a study of 350 patients with 1 or more compression fracture without conal compromise or spinal nerve compression. They found 240 of the 350 patients complained of additional nonmidline pain. The pain was typically in the ribs, hip, groin, or buttocks. Treatment of the fracture with vertebroplasty (see Other Treatment) resulted in 83% of those patients gaining pain relief. Therefore, the possibility of the fracture causing referred pain outside the spine may be very real (Gibson, 2006). Alternatively, many compression fractures are painless. Osteoporosis is a silently progressive disease. Compression fractures are often diagnosed when an elderly patient presents with symptoms such as progressive scoliosis or mechanical lower back pain and the physician obtains routine lumbar radiographs. Finally, patients may present with a known (or unknown) malignancy. Routine spinal screening via MRI (if focal or referred pain occurs), or via bone scan (as a survey if pain has not occurred) reveals the pathologic fracture. The most common malignancies leading to spinal involvement in the form of fractures are metastasis and multiple myeloma. Often, the compression fracture is the presenting symptom or finding that leads to the diagnosis of malignancy. However, patients may have unexplained fevers, night sweats, past history of malignancy, or weight loss. Finally, patients who have recently traveled outside of the United States, or who live in the inner city, may have symptoms of infection, such as general malaise, fever, or severely increasing pain. In these patients, osteomyelitis and Pott disease (tuberculosis spondylitis) must be ruled out. PhysicalA detailed neurologic examination is essential in all patients presenting with back pain, spine deformity, or traumatic spine injury. Most interventional procedures to alleviate pain in compression fractures are contraindicated in cases of neurologic compromise. Thus, a rectal examination is required to assess for rectal tone and sensation in trauma patients. Upon inspection of the spine, the patient typically has a kyphotic posture that cannot be corrected. The kyphosis is caused by the wedge shape of the fracture, essentially turning squares to triangles. Hip flexor contractures due to iliopsoas shortening are typically present. Palpation is important to correlate any reports of pain to the radiographic level of injury. Extreme pain elicited with superficial palpation is often observed in patients with spinal infections. Moderate pain is usually present at the level of the fracture. CausesThe main risk factor leading to an increased frequency of lumbar compression fractures is osteoporosis. In females, the leading risk factor increasing the likelihood of osteoporosis is menopause, or estrogen deficiency. Additional risk factors that may worsen the severity of osteoporosis include cigarette smoking, physical inactivity, use of prednisone and other medications, and poor nutrition. In males, all of the above risk factors apply; however, low testosterone levels also may be associated with compression fractures. Renal failure and liver failure are both associated with osteopenia of bones. Nutritional deficiencies can decrease bone remodeling and increase osteopenia. Finally, genetics also play a role in the development of compression fractures; osteoporosis can be observed in closely related family members. Malignancy may manifest initially as a compression fracture. The most common malignancy in the spine is metastasis. Typical malignancies that metastasize to the spine are renal cell, prostate, breast, and lung, although other types can metastasize to the spine on rare occasions. The 2 most common primary spine malignancies are multiple myeloma and lymphoma. Infection that results in osteomyelitis can also result in a compression fracture. Typically, the most common organisms in a chronic infection are staphylococci or streptococci. Tuberculosis in the spine can occur and is called Pott disease. DIFFERENTIALSCoccyx Pain Lumbar Degenerative Disk Disease Lumbar Facet Arthropathy Lumbar Spondylolysis and Spondylolisthesis Mechanical Low Back Pain Osteoporosis (Primary) Osteoporosis (Secondary)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Acetaminophen with codeine (Tylenol with codeine) |
|---|---|
| Description | A centrally acting analgesic, often appropriate in elderly patients with moderate back pain. |
| Adult Dose | 1 tab PO q4-6h prn; often a tid/qid dosing schedule can prevent cycling of pain; not to exceed 4000 mg/d; codeine can then be given independent of acetaminophen |
| Pediatric Dose | Administer weight-based dosing |
| Contraindications | Documented hypersensitivity |
| Interactions | Toxicity increases with CNS depressants or TCAs |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Caution in patients dependent on opiates because this substitution may result in acute opiate withdrawal symptoms; caution in severe renal or hepatic dysfunction |
| Drug Name | Oxycodone (OxyContin, OxyIR, Roxicodone) |
|---|---|
| Description | Reserved for patients with more severe back pain from their fracture; can be given in short- or long-acting form. |
| Adult Dose | 5-10 mg PO q4-6h prn; 10-20 mg of long-acting form can be given bid with fewer fluctuations in pain level |
| Pediatric Dose | Not established |
| Contraindications | Documented history of dependence or abuse of these medications; need to operate heavy machinery or drive |
| Interactions | Phenothiazines may antagonize analgesic effects; MAOIs, general anesthesia, CNS depressants, and TCAs may increase toxicity |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Pregnancy category D if used for prolonged periods or in high doses; caution in COPD, emphysema, and renal insufficiency |
| Drug Name | Acetaminophen (Tylenol, Panadol, Feverall) |
|---|---|
| Description | DOC for pain in patients with documented hypersensitivity to aspirin or NSAIDs, with upper GI disease, or who are taking oral anticoagulants. |
| Adult Dose | 375-650 mg PO q4-6h prn or 1000 mg PO q6-8h prn; not to exceed 4 g/d |
| Pediatric Dose | <12 years: 10-15 mg/kg/dose PO q4-6h prn; not to exceed 2.6 g/d >12 years: 325-650 mg PO q4h; not to exceed 5 doses in 24 h |
| Contraindications | Documented hypersensitivity; known G-6-P deficiency |
| Interactions | Rifampin can reduce analgesic effects; coadministration with barbiturates, carbamazepine, hydantoins, and isoniazid may increase hepatotoxicity |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Hepatotoxicity possible in people with long-term alcoholism following various dose levels; severe or recurrent pain or high or continued fever may indicate a serious illness; acetaminophen is contained in many OTC products and combined use with these products may result in cumulative doses exceeding recommended maximum dose |
| Drug Name | Tramadol hydrochloride (Ultram); tramadol and acetaminophen (Ultracet) |
|---|---|
| Description | Centrally acting analgesics. Although mode of action is not completely understood, from animal tests, at least 2 complementary mechanisms appear applicable: binding of parent and M1 metabolite to micro-opioid receptors and weak inhibition of reuptake of norepinephrine and serotonin. |
| Adult Dose | Ultram: 50-100 mg PO q6-8h Ultracet: 37.5-75 mg tramadol dose PO q6-8h Ultram long acting (24 h): 100-300 mg PO qd |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; opioid-dependent patients; concurrent use of MAOI or within 14 d; use of SSRIs, TCAs, or opioids; acute alcohol intoxication |
| Interactions | Significantly decrease carbamazepine effects; cimetidine increases toxicity; risk of serotonin syndrome with coadministration of antidepressants |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Seizures have been reported in patients receiving Ultram within the recommended dosage range; spontaneous postmarketing reports indicate that seizure risk is increased with doses of Ultram above the recommended dosing range; risk of convulsions may also increase in patients with epilepsy, history of seizures, or a recognized risk for seizure (eg, head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections); in Ultram overdose, naloxone administration may increase risk of seizure; administer Ultram cautiously in patients at risk for respiratory depression; may impair mental and or physical abilities required for performance of potentially hazardous tasks such as driving car or operating machinery |
| Drug Name | Oxycodone and acetaminophen (Percocet) |
|---|---|
| Description | Drug combination indicated for relief of moderate to severe pain. |
| Adult Dose | 1-2 tab/cap PO q4-6h prn for pain |
| Pediatric Dose | 0.05-0.15 mg/kg/dose oxycodone PO; not to exceed 5 mg/dose of oxycodone PO q4-6h prn |
| Contraindications | Documented hypersensitivity |
| Interactions | Phenothiazines may decrease analgesic effects; toxicity increases with coadministration of either CNS depressants or TCAs |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Duration of action may increase in elderly patients; be aware of total daily dose of acetaminophen patient is receiving; do not exceed 4000 mg acetaminophen in 24 h; higher doses may cause liver toxicity |
| Drug Name | Hydromorphone (Dilaudid) |
|---|---|
| Description | Potent semisynthetic opiate agonist similar in structure to morphine. Approximately 7-8 times as potent as morphine on mg-to-mg basis with shorter or similar duration of action. |
| Adult Dose | 1-4 mg PO q4-6h prn; alternatively, 1-2 mg IV/IM/SC q4-6h prn; adjust dose according to pain scale assessment |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; obstetrical analgesia, increased intracranial pressure, respiratory depression, ulcerative colitis, Crohn disease, abdominal cramping and distention |
| Interactions | Hydantoins may decrease effects; phenothiazines, CNS depressants, and TCAs may increase toxicity |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Pregnancy category D in prolonged use or high doses at term; caution in patients with head injuries because may increase respiratory depression and CSF pressure (use only if absolutely necessary); caution postoperatively and with history of pulmonary disease (suppresses cough reflex); increased dosing levels, due to tolerance, may aggravate or cause seizures (even without prior history); adjust dose in renal insufficiency (do not use in severe renal dysfunction); normeperidine metabolite accumulation may induce CNS toxicity; monitor closely for morphine-induced seizure activity if prior seizure history |
| Drug Name | Fentanyl (Duragesic) |
|---|---|
| Description | A synthetic opioid that is 75-200 times more potent with much shorter half-life than morphine sulfate. Has less hypotensive effects and is safer in patients with hyperactive airway disease than morphine because of minimal-to-no associated histamine release. By itself, it causes little cardiovascular compromise, although addition of benzodiazepines or other sedatives may result in decreased cardiac output and blood pressure. Highly lipophilic and protein-bound. Prolonged exposure leads to accumulation in fat and delays weaning process. Consider continuous infusion because of short half-life. Parenteral form is DOC for conscious sedation analgesia. Ideal for analgesic action of short duration during anesthesia and during immediate postoperative period. Excellent choice for pain management and sedation of short duration (30-60 min) and easy to titrate. Easily and quickly reversed by naloxone. After initial parenteral dose, subsequent parenteral doses should not be titrated more frequently than q3h or q6h thereafter. Transdermal form is used only for chronic pain conditions in opioid-tolerant patients. When using transdermal dosage form, most patients are controlled with 72-h dosing intervals; however, some require dosing intervals of 48 h. |
| Adult Dose | Emergency: 0.5-2 mcg/kg/dose IM/IV Analgesia: 0.5-1 mcg/kg/dose IM/IV q30-60min Transdermal: Apply a 25-mcg/h system q48-72h |
| Pediatric Dose | <2 years: 2-3 mcg/kg/dose IM/IV q30-60min 2-12 years: 1-2 mcg/kg/dose IM/IV q60min >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; hypotension or potentially compromised airway in which establishing rapid airway control would be difficult |
| Interactions | Phenothiazines may antagonize analgesic effects of opiate agonists; TCAs may potentiate adverse effects when both drugs are used concurrently |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in hypotension, respiratory depression, constipation, nausea, emesis, and urinary retention; idiosyncratic reaction known as chest wall rigidity syndrome may require neuromuscular blockade in order to increase ventilation |
| Drug Name | Morphine sulfate (Roxanol, MSIR, MS Contin) |
|---|---|
| Description | DOC for analgesia due to reliable and predictable effects, safety profile, and ease of reversibility with naloxone. Various IV doses are used; commonly titrated until desired effect obtained. |
| Adult Dose | Starting dose: 0.1 mg/kg IV/IM/SC Maintenance dose: 5-20 mg/70 kg IV/IM/SC q4h Relatively hypovolemic patients: Start with 2 mg IV/IM/SC; reassess hemodynamic effects of dose |
| Pediatric Dose | Infants and children: 0.1-0.2 mg/kg dose IV/IM/SC q2-4h prn; not to exceed 15 mg/dose; may initiate at 0.05 mg/kg/dose |
| Contraindications | Documented hypersensitivity; hypotension; potentially compromised airway in which establishing rapid airway control would be difficult |
| Interactions | Phenothiazines may antagonize analgesic effects of opiate agonists; TCAs, MAOIs, and other CNS depressants may potentiate adverse effects |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in hypotension, respiratory depression, nausea, emesis, constipation, urinary retention, atrial flutter, and other supraventricular tachycardias; has vagolytic action and may increase ventricular response rate |
Stimulate new bone formation on trabecular and cortical (periosteal and/or endosteal) bone surfaces by preferential stimulation of osteoblastic activity over osteoclastic activity.
| Drug Name | Teriparatide (Forteo) |
|---|---|
| Description | Recombinant human parathyroid hormone rhPTH(1-34), which has identical sequence to 34 N-terminal amino acids (biologically active region) of 84-amino acid human parathyroid hormone. Acts as endogenous parathyroid hormone, thus regulating calcium and phosphate metabolism in bone and kidney. Works primarily to stimulate new bone by increasing number and activity of osteoblasts (bone-forming cells). Additional physiological actions include regulation of bone metabolism, renal tubular reabsorption of calcium and phosphate, and intestinal calcium absorption. When administered with calcium and vitamin D, teriparatide increases bone mineral density and decreases risk of fractures in patients with osteoporosis. |
| Adult Dose | 20 mcg SC qd |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; increased risk for osteosarcoma (including those with Paget disease of bone or unexplained elevations of alkaline phosphatase, open epiphyses, or prior radiation therapy involving the skeleton); children or growing adults; patients with bone metastases or history of skeletal malignancies and those with metabolic bone diseases other than osteoporosis |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Monitor for hypercalcemia; may cause orthostatic hypotension (particularly following first several doses), dizziness, or leg cramps |
Used to prevent worsening of osteoporosis and occasionally can reverse the process.
| Drug Name | Calcitonin (Miacalcin, Osteocalcin) |
|---|---|
| Description | Administered most often intranasally. Advantage is that it also can relieve some of the back pain associated with fracture. |
| Adult Dose | 1 puff 200 IU/d in alternating nostrils; 100 IU SC qd/qod |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Hypocalcemia may occur; examine urine sediment during prolonged therapy |
Analogs of pyrophosphate and act by binding to hydroxyapatite in bone matrix, thereby inhibiting dissolution of crystals. Prevent osteoclast attachment to bone matrix and osteoclast recruitment and viability.
| Drug Name | Alendronate (Fosamax) |
|---|---|
| Description | A bisphosphonate that acts as a specific inhibitor of osteoclast-mediated bone resorption. Patients should be upright and not lie down for 30 min after taking medication. |
| Adult Dose | 10 mg PO qd; must take at least 30 min before first food intake of day |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; abnormalities of the esophagus that delay esophageal emptying; inability to sit upright for at least 30 min; hypocalcemia |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Hypocalcemia must be corrected before initiating treatment; not recommended for patients with renal insufficiency |
May act like estrogen to prevent bone resorption.
| Drug Name | Raloxifene hydrochloride (Evista) |
|---|---|
| Description | Selective estrogen receptor modulator that decreases bone loss. |
| Adult Dose | 60 mg PO qd |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; breastfeeding; women who could become pregnant; history of thromboembolic events |
| Interactions | Concomitant use with estrogen replacement medication not recommended; coadministration of cholestyramine not recommended |
| Pregnancy | D - Unsafe in pregnancy |
| Precautions | Not associated with an increased risk of breast cancer; hot flashes and leg cramps are most common adverse effects |
| Media file 1: Anteroposterior and lateral radiographs of an L1 osteoporotic wedge compression fracture. | |
![]() | View Full Size Image | Media type: X-RAY |
| Media file 2: Fluoroscopic view of a kyphoplasty procedure. | |
![]() | View Full Size Image | Media type: X-RAY |
Lumbar Compression Fracture excerpt
Article Last Updated: Feb 10, 2007